Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on July 30, 2019, covering events occurring on July 25, 2019. The Company is an emerging growth company incorporated in Nevada with its principal executive offices in La Jolla, California. The filing primarily serves as a Regulation FD disclosure regarding an upcoming corporate presentation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing focuses solely on the announcement of executive participation in an industry conference.
Guidance, Outlook, and Management Commentary
- Upcoming Presentation: On July 25, 2019, the Company announced that C.J. Barnum, Director of Neuroscience, and R.J. Tesi, M.D., CEO, will present at the 17th Annual Congress of International Drug Discovery Science & Technology.
- Event Details: The presentation is scheduled for July 26, 2019, in Japan.
- Exhibit Status: The press release detailing this event is furnished as Exhibit 99.1 but is explicitly not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the content of the press release (Exhibit 99.1) for specific scientific or business updates regarding the presentation.
- Confirm the Company's status as an emerging growth company and any associated reporting exemptions.
- Review subsequent filings for any financial data or operational updates resulting from the July 26, 2019, conference.